Many efforts have been made to develop more effective and safer inhibitors of PI3K/AKT and EGFR signaling pathways, however, clinical evaluation of PI3K inhibitors in HNSCC is currently in early phase of clinical trials [7]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.